688302 海创药业
已收盘 07-18 15:00:01
资讯
新帖
简况
海创药业-U07月18日获主力加仓36万元 环比增加414.29%
自选股智能写手 · 07-18 15:18
海创药业-U07月18日获主力加仓36万元 环比增加414.29%
海创药业（688302）7月15日主力资金净卖出372.09万元
证券之星 · 07-16 08:22
海创药业（688302）7月15日主力资金净卖出372.09万元
7月12日海创药业发生1笔大宗交易 成交金额761.08万元
证券之星 · 07-12
7月12日海创药业发生1笔大宗交易 成交金额761.08万元
7月11日海创药业-U涨5.21%，鹏华创新增长一年持有期混合A基金重仓该股
证券之星 · 07-11
7月11日海创药业-U涨5.21%，鹏华创新增长一年持有期混合A基金重仓该股
海创药业-U涨5.21%，西南证券二个月前给出“买入”评级
证券之星 · 07-11
海创药业-U涨5.21%，西南证券二个月前给出“买入”评级
海创药业-U大幅上涨 获北向资金减持0.02万股
智选洞察 · 07-11
海创药业-U大幅上涨 获北向资金减持0.02万股
海创药业-U大幅上涨 获北向资金减持0.33万股
智选洞察 · 07-08
海创药业-U大幅上涨 获北向资金减持0.33万股
海创药业最新公告：HP537片用于治疗血液系统恶性肿瘤的临床I/II期试验申请获得美国FDA批准
证券之星 · 07-07
海创药业最新公告：HP537片用于治疗血液系统恶性肿瘤的临床I/II期试验申请获得美国FDA批准
海创药业(688302.SH)：HP537片用于治疗血液系统恶性肿瘤的临床I/II期试验获FDA批准
智通财经 · 07-07
海创药业(688302.SH)：HP537片用于治疗血液系统恶性肿瘤的临床I/II期试验获FDA批准
海创药业-U涨9.19%，西南证券二个月前给出“买入”评级
证券之星 · 07-05
海创药业-U涨9.19%，西南证券二个月前给出“买入”评级
四川板块盘中拉升，海创药业-U涨11.70%
自选股智能写手 · 07-05
四川板块盘中拉升，海创药业-U涨11.70%
7月4日海创药业-U跌6.99%，鹏华创新增长一年持有期混合A基金重仓该股
证券之星 · 07-04
7月4日海创药业-U跌6.99%，鹏华创新增长一年持有期混合A基金重仓该股
海创药业（688302）7月3日主力资金净买入331.35万元
证券之星 · 07-04
海创药业（688302）7月3日主力资金净买入331.35万元
海创药业HP518片获FDA快速通道认定 PROTAC技术保持国内领先
证券之星 · 07-03
海创药业HP518片获FDA快速通道认定 PROTAC技术保持国内领先
海创药业-U大幅上涨 获北向资金连续6日减持
智选洞察 · 07-03
海创药业-U大幅上涨 获北向资金连续6日减持
海创药业：目前暂不涉及因财务类指标被实施退市风险警示
每日经济新闻 · 07-02
海创药业：目前暂不涉及因财务类指标被实施退市风险警示
海创药业一款在研新药在美国获快速通道认定，用于AR三阴乳腺癌
新京报 · 07-01
海创药业一款在研新药在美国获快速通道认定，用于AR三阴乳腺癌
海创药业最新公告：HP518片获美国FDA授予快速通道认定
证券之星 · 06-30
海创药业最新公告：HP518片获美国FDA授予快速通道认定
海创药业：HP518片拟用于治疗雄激素受体（AR）阳性三阴乳腺癌获美国FDA授予快速通道认定
证券时报 · 06-30
海创药业：HP518片拟用于治疗雄激素受体（AR）阳性三阴乳腺癌获美国FDA授予快速通道认定
海创药业（688302）6月28日主力资金净买入19.59万元
证券之星 · 06-29
海创药业（688302）6月28日主力资金净买入19.59万元
加载更多
公司概况
公司名称：
海创药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-04-12
主营业务：
海创药业股份有限公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台，以开发具有重大临床需求的Best-in-class（同类最佳）、First-in-class（国际首创）药物为目标的国际化创新药企业。公司的主要产品为肿瘤、代谢性疾病药品。公司在肿瘤和代谢性疾病领域重点布局，重点搭建了氘代药物研发平台、PROTAC靶向蛋白降解技术平台、靶向药物发现与验证平台与先导化合物优化筛选平台，形成了较强的研发优势和丰富的技术储备。
发行价格：
42.92
{"stockData":{"symbol":"688302","market":"SH","secType":"STK","nameCN":"海创药业","latestPrice":25.5,"timestamp":1721286001000,"preClose":25.69,"halted":0,"volume":566815,"delay":0,"floatShares":72724500,"shares":99015600,"eps":-2.6865,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.19,"latestTime":"07-18 15:00:01","open":25.32,"high":25.74,"low":24.95,"amount":14356800,"amplitude":0.0308,"askPrice":25.5,"askSize":1,"bidPrice":25.49,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-2.6865,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721352600000},"adr":0,"adjPreClose":25.69,"symbolType":"stock_kcb","openAndCloseTimeList":[[1721266200000,1721273400000],[1721278800000,1721286000000]],"highLimit":28.26,"lowLimit":23.12,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":99015598,"pbRate":1.9,"roa":"--","roe":"--","epsLYR":-2.97,"committee":-0.589744,"marketValue":2525000000,"floatMarketCap":1854000000,"peRate":-9.491904,"changeRate":-0.0074,"turnoverRate":0.0078,"status":1,"afterMarket":{"amount":0,"volume":0,"close":25.5,"buyVolume":0,"sellVolume":0,"time":1721288039754,"indexStatus":"已收盘 07-18 15:30:00","preClose":25.69}},"requestUrl":"/m/hq/s/688302","defaultTab":"news","newsList":[{"id":"2452175520","title":"海创药业-U07月18日获主力加仓36万元 环比增加414.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452175520","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452175520?lang=zh_cn&edition=full","pubTime":"2024-07-18 15:18","pubTimestamp":1721287131,"startTime":"0","endTime":"0","summary":"07月18日, 海创药业-U股价跌0.74%，报收25.50元，成交金额1435万元，换手率0.78%，振幅3.08%，量比0.45。海创药业-U今日主力资金净流入36万元，上一交易日主力净流入7万元，今日环比增加414.29%。|07月18日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|双乐股份|5.48%|#|蓝英装备|4.15%|#|兴民智通|2.90%|#|法尔胜|2.86%|#|东方嘉盛|2.81%|#|上海贝岭|2.68%|#|南京商旅|2.67%|#|华东数控|2.63%|#|天迈科技|2.40%|#|北方长龙|2.22%|海创药业-U所在的化学制药行业，今日主力净流入635万元，行业排名44/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071815304395d3e529&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071815304395d3e529&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2451881749","title":"海创药业（688302）7月15日主力资金净卖出372.09万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451881749","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451881749?lang=zh_cn&edition=full","pubTime":"2024-07-16 08:22","pubTimestamp":1721089326,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月15日收盘，海创药业报收于25.75元，下跌3.92%，换手率1.82%，成交量1.32万手，成交额3469.59万元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入313.13万元，融资偿还192.28万元，融资净买入120.85万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071600013220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2450630133","title":"7月12日海创药业发生1笔大宗交易 成交金额761.08万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450630133","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450630133?lang=zh_cn&edition=full","pubTime":"2024-07-12 17:20","pubTimestamp":1720776034,"startTime":"0","endTime":"0","summary":"证券之星消息，7月12日海创药业发生大宗交易，交易数据如下：大宗交易成交价格27.23元，相对当日收盘价溢价1.6%，成交27.95万股，成交金额761.08万元，买方营业部为恒泰证券股份有限公司上海曲阳路证券营业部，卖方营业部为西部证券股份有限公司上海第三分公司。近三个月该股共发生2笔大宗交易，合计成交9851.0手，折价成交1笔，溢价成交1笔。截至2024年7月12日收盘，海创药业报收于26.8元，上涨5.3%，换手率3.54%，成交量2.58万手，成交额6961.97万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071200036551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2450380190","title":"7月11日海创药业-U涨5.21%，鹏华创新增长一年持有期混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450380190","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450380190?lang=zh_cn&edition=full","pubTime":"2024-07-11 16:16","pubTimestamp":1720685818,"startTime":"0","endTime":"0","summary":"证券之星消息，7月11日海创药业-U涨5.21%，收盘报25.45元，换手率1.24%，成交量9010.0手，成交额2284.25万元。重仓海创药业-U的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为鹏华创新增长一年持有期混合A。鹏华创新增长一年持有期混合A目前规模为1.13亿元，最新净值0.8272，较上一交易日下跌0.3%，近一年下跌15.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071100030033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239","160613"],"gpt_icon":0},{"id":"2450175380","title":"海创药业-U涨5.21%，西南证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2450175380","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450175380?lang=zh_cn&edition=full","pubTime":"2024-07-11 16:16","pubTimestamp":1720685811,"startTime":"0","endTime":"0","summary":"今日海创药业-U涨5.21%，收盘报25.45元。2024年4月15日，西南证券研究员杜向阳发布了对海创药业的研报《2023年报点评：氘恩扎卢胺有望2024年底获批上市》，该研报对海创药业给出“买入”评级。研报中预计公司2024-2026年实现营业收入分别约为0.1、1.6、3.8亿元。考虑海创药业研发实力强劲，氘代和PROTAC技术平台实力出众，首款创新药德恩鲁胺NDA已获受理，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为财通证券的华挺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071100030027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","600369"],"gpt_icon":0},{"id":"2450877061","title":"海创药业-U大幅上涨 获北向资金减持0.02万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450877061","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450877061?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:15","pubTimestamp":1720664121,"startTime":"0","endTime":"0","summary":"07月11日，海创药业-U股价大幅上涨，截至10点15分，海创药业-U上涨5.00%，报25.40元/股，成交625万元，换手率0.34%，振幅3.31%。资金动向截止发稿，海创药业-U获得主力净流入48万元。北向资金方面，海创药业-U07月10日获得北向资金减持0.02万股，截至07月10日，北向资金当前共持有海创药业-U4.08万股，市值103万元，持股占流通股比为0.05%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711101604aef91b59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711101604aef91b59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2449181417","title":"海创药业-U大幅上涨 获北向资金减持0.33万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449181417","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449181417?lang=zh_cn&edition=full","pubTime":"2024-07-08 09:30","pubTimestamp":1720402203,"startTime":"0","endTime":"0","summary":"07月08日，海创药业-U股价大幅上涨，截至09点30分，海创药业-U上涨5.81%，报26.77元/股，成交149万元，换手率0.08%，振幅3.79%。资金动向截止发稿，海创药业-U获得主力净流入58万元，其中超大单流入133万元，大单流出75万元。北向资金方面，海创药业-U07月04日获得北向资金减持0.33万股，截至07月04日，北向资金当前共持有海创药业-U4.19万股，市值112万元，持股占流通股比为0.05%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708093054af90ed84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708093054af90ed84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2449550457","title":"海创药业最新公告：HP537片用于治疗血液系统恶性肿瘤的临床I/II期试验申请获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2449550457","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449550457?lang=zh_cn&edition=full","pubTime":"2024-07-07 16:50","pubTimestamp":1720342223,"startTime":"0","endTime":"0","summary":"海创药业公告，公司自主研发的HP537片用于治疗血液系统恶性肿瘤的临床I/II期试验申请正式获得FDA批准。此前，HP537片中国临床试验申请已于2024年2月获国家药品监督管理局批准。经查询，截至本公告披露日，国内外均无同类靶点产品获批上市。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070700001739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2449244755","title":"海创药业(688302.SH)：HP537片用于治疗血液系统恶性肿瘤的临床I/II期试验获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2449244755","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449244755?lang=zh_cn&edition=full","pubTime":"2024-07-07 16:47","pubTimestamp":1720342041,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海创药业 发布公告，近日，公司收到美国食品药品监督管理局签发的《临床研究继续进行通知书》，公司自主研发的HP537片用于治疗血液系统恶性肿瘤的临床I/II期试验申请正式获得FDA批准。根据临床前体内外药效学研究结果，HP537片有望成为治疗血液系统恶性肿瘤并具有重要临床价值的有效药物。此前，HP537片中国临床试验申请已于2024年2月获NMPA批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2449025382","title":"海创药业-U涨9.19%，西南证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2449025382","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449025382?lang=zh_cn&edition=full","pubTime":"2024-07-05 16:15","pubTimestamp":1720167351,"startTime":"0","endTime":"0","summary":"今日海创药业-U涨9.19%，收盘报25.3元。2024年4月15日，西南证券研究员杜向阳发布了对海创药业的研报《2023年报点评：氘恩扎卢胺有望2024年底获批上市》，该研报对海创药业给出“买入”评级。考虑海创药业研发实力强劲，氘代和PROTAC技术平台实力出众，首款创新药德恩鲁胺NDA已获受理，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为财通证券的华挺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500029563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","688302"],"gpt_icon":0},{"id":"2449363652","title":"四川板块盘中拉升，海创药业-U涨11.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449363652","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449363652?lang=zh_cn&edition=full","pubTime":"2024-07-05 14:03","pubTimestamp":1720159390,"startTime":"0","endTime":"0","summary":"07月05日，四川板块盘中拉升，截至14点03分，四川板块整体指数上涨1.01%，报3074.750点。从个股上来看，该板块的成分股中，海创药业-U涨11.70%，圣诺生物、安控科技等3只股涨幅超过5%。从资金上来看，截止发稿，四川板块主力净流入为-3.38亿，其中通威股份受到资金热捧，主力净流入3109.14万；拉长时间线来看，该板块近20日主力资金净流入-150.52亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070514031096819f85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070514031096819f85&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2448941439","title":"7月4日海创药业-U跌6.99%，鹏华创新增长一年持有期混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448941439","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448941439?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:21","pubTimestamp":1720081274,"startTime":"0","endTime":"0","summary":"证券之星消息，7月4日海创药业-U跌6.99%，收盘报23.17元，换手率1.57%，成交量1.14万手，成交额2717.48万元。重仓海创药业-U的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为鹏华创新增长一年持有期混合A。鹏华创新增长一年持有期混合A目前规模为1.13亿元，最新净值0.8637，较上一交易日下跌0.03%，近一年下跌11.49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400030665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["160613","BK0239","688302"],"gpt_icon":0},{"id":"2448452927","title":"海创药业（688302）7月3日主力资金净买入331.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448452927","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448452927?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:11","pubTimestamp":1720051877,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月3日收盘，海创药业报收于24.91元，上涨5.77%，换手率1.55%，成交量1.13万手，成交额2757.96万元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入216.65万元，融资偿还166.62万元，融资净买入50.02万元，连续3日净买入累计98.15万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400010964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2448108312","title":"海创药业HP518片获FDA快速通道认定 PROTAC技术保持国内领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2448108312","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448108312?lang=zh_cn&edition=full","pubTime":"2024-07-03 18:28","pubTimestamp":1720002507,"startTime":"0","endTime":"0","summary":"近日，海创药业股份有限公司公告显示，其在研药物HP518片获得美国食品药品监督管理局的“快速通道认定”。此次HP518片获FDA“快速通道认定”，将有助于海创药业加快药物后续研发和批准上市。诺华与Arvinas的交易协议再度将PROTAC技术推向了聚光灯下。其中，海创药业PROTAC技术保持国内领先，多款创新药进入临床。本次HP518片获得美国FDA“快速通道认定”，标志着公司PROTAC药物研发获得国际权威机构的认可，为公司后续产品的商业化进程奠定了坚实基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703183308956d443e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703183308956d443e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2448314172","title":"海创药业-U大幅上涨 获北向资金连续6日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2448314172","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448314172?lang=zh_cn&edition=full","pubTime":"2024-07-03 11:14","pubTimestamp":1719976449,"startTime":"0","endTime":"0","summary":"07月03日，海创药业-U股价大幅上涨，截至11点14分，海创药业-U上涨5.31%，报24.80元/股，成交1213万元，换手率0.69%，振幅5.35%。资金动向截止发稿，海创药业-U获得主力净流入312万元。北向资金方面，海创药业-U06月28日获得北向资金减持0.22万股连续6日减持，截至06月28日，北向资金当前共持有海创药业-U4.55万股，市值112万元，持股占流通股比为0.06%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703111421aef7b0d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703111421aef7b0d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2448862851","title":"海创药业：目前暂不涉及因财务类指标被实施退市风险警示","url":"https://stock-news.laohu8.com/highlight/detail?id=2448862851","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448862851?lang=zh_cn&edition=full","pubTime":"2024-07-02 15:36","pubTimestamp":1719905772,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问，如果2025年公司的主营收入低于1亿元，是否会触及上海科创板退市规则？海创药业（688302.SH）7月2日在投资者互动平台表示，根据《上海证券交易所科创板股票上市规则》(2024年4月修订)，本公司自上市之日起第4个完整会计年度起（2026年年度报告）适用财务指标相关规定情形。公司目前暂不涉及因财务类指标被实施退市风险警示。(记者 毕陆名)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021536429ef2ddb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021536429ef2ddb1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2448999597","title":"海创药业一款在研新药在美国获快速通道认定，用于AR三阴乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2448999597","media":"新京报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448999597?lang=zh_cn&edition=full","pubTime":"2024-07-01 19:12","pubTimestamp":1719832351,"startTime":"0","endTime":"0","summary":"新京报讯 6月30日，海创药业宣布，其在研1类新药蛋白降解靶向嵌合体HP518片获得美国食品药品监督管理局授予“快速通道认定”，用于治疗雄激素受体阳性三阴乳腺癌。目前国内外均无同类靶点产品获批上市。AR阳性三阴乳腺癌患者约占三阴乳腺癌患者的15%-50%。AR通过非配体依赖的全新机理调节三阴乳腺癌细胞生长，导致AR抑制剂疗效欠佳。临床前药效学研究结果发现，HP518片显示出了显著的抗肿瘤活性，并具备联合三阴乳腺癌一线用药的潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240701191638955ea851&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240701191638955ea851&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2447867621","title":"海创药业最新公告：HP518片获美国FDA授予快速通道认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2447867621","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447867621?lang=zh_cn&edition=full","pubTime":"2024-06-30 16:29","pubTimestamp":1719736197,"startTime":"0","endTime":"0","summary":"海创药业公告，HP518片获得FDA快速通道认定。该药物是一种蛋白降解靶向联合体（PROTAC）药物，属于化学药品1类，临床拟用于治疗转移性去势抵抗性前列腺癌（mCRPC）以及雄激素受体（AR）阳性三阴乳腺癌。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024063000001316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2447676682","title":"海创药业：HP518片拟用于治疗雄激素受体（AR）阳性三阴乳腺癌获美国FDA授予快速通道认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2447676682","media":"证券时报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447676682?lang=zh_cn&edition=full","pubTime":"2024-06-30 16:23","pubTimestamp":1719735792,"startTime":"0","endTime":"0","summary":"证券时报e公司讯，海创药业(688302)6月30日晚间公告，近日公司在研品种HP518片收到美国食品药品监督管理局（简称“FDA”）授予“快速通道认定”用于治疗雄激素受体（AR）阳性三阴乳腺癌。目前国内外均无同类靶点产品获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024063016231795567f4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024063016231795567f4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2447652270","title":"海创药业（688302）6月28日主力资金净买入19.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2447652270","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447652270?lang=zh_cn&edition=full","pubTime":"2024-06-29 08:21","pubTimestamp":1719620476,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月28日收盘，海创药业报收于23.56元，下跌2.48%，换手率1.46%，成交量1.06万手，成交额2546.7万元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入116.99万元，融资偿还357.65万元，融资净偿还240.66万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062900012687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-04-12","address":"四川省成都市武侯区高新区科园南路5号蓉药大厦1栋4层附2、3号","stockEarnings":[{"period":"1week","weight":0.002},{"period":"1month","weight":-0.0834},{"period":"3month","weight":0.0245},{"period":"6month","weight":-0.4239},{"period":"1year","weight":-0.4772},{"period":"ytd","weight":-0.5103}],"companyName":"海创药业股份有限公司","boardCode":"AI0027","perCapita":"20195股","boardName":"医药制造业","registeredCapital":"9901万元","compareEarnings":[{"period":"1week","weight":0.0023},{"period":"1month","weight":-0.0175},{"period":"3month","weight":-0.0288},{"period":"6month","weight":0.0511},{"period":"1year","weight":-0.0693},{"period":"ytd","weight":0.0007}],"survey":" 海创药业股份有限公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台，以开发具有重大临床需求的Best-in-class（同类最佳）、First-in-class（国际首创）药物为目标的国际化创新药企业。公司的主要产品为肿瘤、代谢性疾病药品。公司在肿瘤和代谢性疾病领域重点布局，重点搭建了氘代药物研发平台、PROTAC靶向蛋白降解技术平台、靶向药物发现与验证平台与先导化合物优化筛选平台，形成了较强的研发优势和丰富的技术储备。","serverTime":1721331474403,"listedPrice":42.92,"stockholders":"3601人(较上一季度增加21.04%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海创药业,688302,海创药业股票,海创药业股票老虎,海创药业股票老虎国际,海创药业行情,海创药业股票行情,海创药业股价,海创药业股市,海创药业股票价格,海创药业股票交易,海创药业股票购买,海创药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}